サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654649

経鼻ドラッグデリバリー技術の世界市場（2025年～2033年）

Global Nasal Drug Delivery Technology Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
経鼻ドラッグデリバリー技術の世界市場（2025年～2033年）
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の経鼻ドラッグデリバリー技術の市場規模は、2024年に816億9,000万米ドルに達し、2033年には1,369億7,000万米ドルに達すると予測され、予測期間2025年～2033年にはCAGR6.7%で成長する見通しです。

経鼻ドラッグデリバリー技術は、治療効果を得るために鼻腔から薬剤を投与することを指します。このドラッグデリバリー経路は、利便性、効率性、胃腸系および肝初回通過代謝をバイパスする能力により、副作用を軽減し、薬物のバイオアベイラビリティを向上させることができるため、ますます使用されるようになっています。経鼻ドラッグデリバリー技術では、鼻腔スプレー、パウダー、エアロゾルを使用して、鼻粘膜から血流に直接薬物を送達します。この方法は、消化管での分解や吸収の悪さにより経口投与では効果が期待できないペプチド、タンパク質、ワクチンなどのドラッグデリバリーに特に有効です。

経鼻ドラッグデリバリー技術の市場需要は、その非侵襲性、利便性、患者のコンプライアンス向上により急速に伸びています。例えば、米国疾病予防管理センターによると、米国では推定1億2,900万人が少なくとも1つの主要な慢性疾患を抱えています。世界保健機関（WHO）によると、2030年までに世界の6人に1人が60歳以上の高齢者となり、この高齢化社会では、より簡単で受け入れやすい治療オプションが必要とされるため、経鼻ドラッグデリバリー技術の需要が高まる見通しです。

市場力学：

促進要因と抑制要因

ナノテクノロジーの進歩

ナノテクノロジーにおける進歩の高まりは、経鼻ドラッグデリバリー技術市場の成長を大きく後押ししており、より効率的で的を絞ったドラッグデリバリーシステムの開発を可能にすることで、予測期間中も市場を牽引していくと予想されます。これらの技術革新は、安定性、バイオアベイラビリティ、患者のコンプライアンスを向上させることにより、鼻腔経路から送達される薬物の有効性を高めます。

例えば、2024年10月、モハリにあるナノ科学技術研究所（INST）の研究者は、中枢神経系結核（CNS-TB）を治療するための新しいドラッグデリバリーシステムを開発しました。この最先端の方法は、血液脳関門（BBB）による制限を克服し、抗結核薬を鼻から脳に直接送達します。

ナノテクノロジーには、鼻粘膜を通過して血流に直接薬剤を運ぶことができるナノ粒子の使用が含まれます。これらのナノ粒子は薬物を分解から守り、安定性と生物学的利用能を高めることができます。これは、経口投与では通常不安定なペプチドやタンパク質にとって特に有益です。

さらに、2024年11月、ウイルスパックス・ファーマシューティカルズは、全米トランスレーショナル・サイエンス推進センター（NCATS）との共同研究開発契約の延長を認められました。この共同研究は、ウイルスパックスの製品候補である経鼻ペプチドNES100の急性および慢性非がん性疼痛の管理を目的とした開発継続のためのものです。NES100は、一種のナノテクノロジー・デリバリー・アプローチに基づくエンケファリン製剤です。エンケファリンは天然に存在する（内因性）ペプチドであり、そのままの形では投与しにくくなっています。

副作用と安全性の懸念

副作用と安全性の懸念は、経鼻ドラッグデリバリー技術市場の成長を妨げる重大な課題です。これらの問題は、患者と医療提供者の両方による経鼻ドラッグデリバリーシステムの受容性と採用に影響を与える可能性があります。経鼻ドラッグデリバリーは時に鼻粘膜に刺激やアレルギー反応を引き起こすことがあります。これは不快感や、患者が点鼻薬や粉末の使用を嫌がることにつながります。乾燥、くしゃみ、鼻づまりといった局所的な副作用は、経鼻ドラッグデリバリー技術でよく見られる問題です。

例えば、アレルギーを治療するためにコルチコステロイドを点鼻薬に使用すると、局所的な刺激が生じ、鼻血や鼻腔の灼熱感につながることがあります。このような副作用は、患者の治療継続意欲を減退させます。

経鼻デリバリーは初回通過代謝を最小限に抑えますが、特に局所的に作用するように意図された薬剤の場合、全身吸収のリスクは依然として存在します。このことは、意図しない全身性の副作用につながる可能性があり、経鼻製剤における特定の薬物の使用を制限する可能性があります。例えば、鼻腔充血除去薬のような局所作用を目的とした薬剤の場合、全身吸収が依然として起こる可能性があり、心拍数や血圧の上昇などの心血管系への影響を引き起こす可能性があります。

目次

第1章 市場イントロダクションと範囲

  • レポートの目的
  • 調査のカバー範囲と定義
  • 調査の対象範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 剤形別のスニペット
  • 用途別のスニペット
  • 流通チャネル別のスニペット
  • 地域別のスニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • ナノテクノロジーの進歩
      • 技術提携と合併の増加
    • 抑制要因
      • 副作用と安全性の懸念
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 経鼻ドラッグデリバリー技術市場：剤形別

  • スプレー剤
  • 点鼻液
  • 粉末剤
  • ジェル剤

第6章 経鼻ドラッグデリバリー技術市場：用途別

  • 呼吸器疾患
    • 喘息
    • 慢性閉塞性肺疾患（COPD）
    • アレルギー性鼻炎
    • 副鼻腔炎
    • その他
  • 中枢神経系疾患
    • 片頭痛
    • パーキンソン病
    • アルツハイマー病
  • 疼痛管理
  • その他

第7章 経鼻ドラッグデリバリー技術市場：流通チャネル別

  • 院内薬局
  • オンライン薬局
  • 小売薬局

第8章 経鼻ドラッグデリバリー技術市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Becton, Dickinson and Company
  • AstraZeneca PLC
  • AptarGroup, Inc.
  • MetP Pharma AG
  • GlaxoSmithKline Inc.
  • Hikma Pharmaceuticals PLC
  • Currax Pharmaceuticals LLC.
  • Tonix Medicines, Inc.
  • Johnson & Johnson

第11章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証とバリデーション

第12章 付録

目次
Product Code: MD9094

The global nasal drug delivery technology market reached US$ 81.69 billion in 2024 and is expected to reach US$ 136.97 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Nasal drug delivery technology refers to the administration of drugs through the nasal cavity to achieve therapeutic effects. This route of drug delivery is increasingly being used for its convenience, efficiency, and ability to bypass the gastrointestinal system and hepatic first-pass metabolism, which can reduce side effects and improve drug bioavailability. Nasal drug delivery technology involves the use of nasal sprays, powders and aerosols to deliver drugs directly into the bloodstream via the nasal mucosa. This method is particularly beneficial for the delivery of peptides, proteins, vaccines and other drugs that may not be effective when administered orally due to degradation in the gastrointestinal tract or poor absorption.

The market demand for nasal drug delivery technology is growing rapidly due to its non-invasive nature, convenience and improved patient compliance. The adoption rate of these technologies is being driven by several factors including increasing applications in chronic disease management, for instance, according to the Centers for Disease Control and Prevention, an estimated 129 million people in the US have at least 1 major chronic disease. According to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over, this aging population requires easier and more acceptable treatment options, which increases the demand for nasal drug delivery technology.

Market Dynamics: Drivers & Restraints

Rising advancements in nanotechnology

The rising advancements in nanotechnology are significantly driving the growth of the nasal drug delivery technology market and are expected to drive the market over the forecast period by enabling the development of more efficient and targeted drug delivery systems. These innovations enhance the effectiveness of drugs delivered through the nasal route by improving their stability, bioavailability and patient compliance.

For instance, in October 2024, researchers from the Institute of Nano Science and Technology (INST), Mohali, developed a novel drug delivery system to treat Central Nervous System Tuberculosis (CNS-TB). This cutting-edge method delivers anti-tuberculosis (TB) drugs directly to the brain through the nasal route, overcoming the limitations posed by the blood-brain barrier (BBB).

Nanotechnology involves the use of nanoparticles that can carry drugs directly across the nasal mucosa into the bloodstream. These nanoparticles can protect drugs from degradation, enhancing their stability and bioavailability. This is particularly beneficial for peptides and proteins, which are typically unstable when administered orally.

Additionally, in November 2024, Virpax Pharmaceuticals, Inc. was granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS). This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.

Adverse effects and safety concerns

Adverse effects and safety concerns are significant challenges hampering the growth of the nasal drug delivery technology market. These issues can impact the acceptability and adoption of nasal drug delivery systems by both patients and healthcare providers. Nasal drug delivery can sometimes cause irritation or allergic reactions in the nasal mucosa. This can lead to discomfort and patient reluctance to use nasal sprays or powders. Localized side effects such as dryness, sneezing or nasal congestion are common issues with nasal drug delivery technologies.

For instance, the use of corticosteroids in nasal sprays for managing allergies can result in local irritation, leading to nosebleeds or a burning sensation in the nasal passages. Such adverse effects can discourage patients from continuing treatment.

Although nasal delivery minimizes first-pass metabolism, there is still a risk of systemic absorption, especially for drugs that are intended to act locally. This can lead to unintended systemic side effects, which can limit the use of certain drugs in nasal formulations. For instance, for drugs intended for local action like nasal decongestants, systemic absorption may still occur, potentially leading to cardiovascular effects such as increased heart rate and blood pressure.

Segment Analysis

The global nasal drug delivery technology market is segmented based on dosage form, application, distribution channel and region.

Application:

The respiratory diseases segment is expected to dominate the nasal drug delivery technology market share

Nasal drug delivery systems are highly effective for treating allergic rhinitis and asthma, which are common respiratory conditions. These conditions require frequent medication administration, and nasal sprays are particularly suitable due to their quick onset of action and localized effects. Nasal corticosteroids are the primary drugs used in this segment, offering targeted anti-inflammatory action directly to the nasal mucosa, which minimizes systemic side effects.

For instance, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, which is developed by AstraZeneca and Avillion, was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

The nasal route allows for quick absorption of drugs into the bloodstream, which is particularly advantageous for managing acute symptoms of respiratory diseases like asthma attacks. Drugs administered via the nasal route can bypass the gastrointestinal system and avoid the first-pass metabolism in the liver, ensuring higher bioavailability and faster therapeutic effects.

Geographical Analysis

North America is expected to hold a significant position in the nasal drug delivery technology market share

Major pharmaceutical companies and research institutions in North America especially in the United States, are investing heavily in the development and commercialization of nasal drug delivery systems. Companies like Pfizer, Johnson & Johnson, Amneal Pharmaceuticals, Inc. and other emerging players have been at the forefront, with nasal drug formulations being a key component of their respiratory disease management strategies by FDA approvals.

For instance, in April 2024, Amneal Pharmaceuticals, Inc. announced the availability of Over the Counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA). Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC NARCAN HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.

Additionally, in September 2024, Renaissance Lakewood, LLC manufactured neffy. The FDA approved and became the first and only needle-free, intranasal spray treatment for Type I allergic reactions, including anaphylaxis in adults and children. neffy is an easy-to-carry and easy-to-use epinephrine medication alternative to needle-based treatments for potentially life-threatening allergic reactions. neffy marks the first regulatory approval worldwide for epinephrine delivered as an intra-nasal spray.

Asia-Pacific is growing at the fastest pace in the nasal drug delivery technology market

The healthcare infrastructure in the Asia-Pacific region has been rapidly improving. Countries like India, China, Japan and South Korea are investing heavily in healthcare, including the establishment of new medical facilities and research centers. For instance, according to the India Brand Equity Foundation (IBEF), under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of US$ 147 million. These rising investments and developments have facilitated the adoption of advanced drug delivery technologies, including nasal drug delivery systems.

In March 2024, Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray. The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray of Organon LLC. The product will be launched in Q1 FY25. Mometasone Furoate Monohydrate Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.

The APAC region is witnessing rapid adoption of new drug delivery technologies, including nanotechnology and controlled release systems for nasal drug delivery. Companies in the region along with strategic partnerships and mergers, innovating and distributing nasal formulations that cater to regional needs. For instance, Altamira Therapeutics Ltd. announced that its associate company Altamira Medica Ltd. agreed with its partner Nuance Pharma, Shanghai, China to extend the territory covered by their exclusive license and distribution agreement for Bentrio nasal spray by several countries across South East and East Asia.

Competitive Landscape

The major global players in the nasal drug delivery technology market include Pfizer Inc., Becton, Dickinson and Company, AstraZeneca PLC, AptarGroup, Inc., MetP Pharma AG, GlaxoSmithKline Inc., Hikma Pharmaceuticals PLC, Currax Pharmaceuticals LLC., Tonix Medicines, Inc., Johnson & Johnson and among others.

Key Developments

  • In October 2024, Aero Pump and Resyca announced their collaboration in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for licensing immediately, this co-developed system represents a new frontier in nasal drug delivery, offering enhanced delivery efficiency, precision and comfort for users.
  • In April 2024, Aptar Pharma launched APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nasal drug delivery technology market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Dosage Form
  • 2.4. Snippet by Application
  • 2.5. Snippet by Distribution Channel
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Nanotechnology
      • 3.1.1.2. Rising Technological Collaborations and Mergers
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Effects and Safety Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Nasal Drug Delivery Technology Market, By Dosage Form

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 5.1.2. Market Attractiveness Index, By Dosage Form
  • 5.2. Sprays*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Drops
  • 5.4. Powders
  • 5.5. Gels

6. Nasal Drug Delivery Technology Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Respiratory Diseases*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Asthma
    • 6.2.4. Chronic Obstructive Pulmonary Disease (COPD)
    • 6.2.5. Allergic Rhinitis
    • 6.2.6. Sinusitis
    • 6.2.7. Others
  • 6.3. CNS Disorders
    • 6.3.1. Migraine
    • 6.3.2. Parkinson's Disease
    • 6.3.3. Alzheimer's Disease
  • 6.4. Pain Management
  • 6.5. Others

7. Nasal Drug Delivery Technology Market, By Distribution Channel

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 7.1.2. Market Attractiveness Index, By Distribution Channel
  • 7.2. Hospital Pharmacies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Nasal Drug Delivery Technology Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Becton, Dickinson and Company
  • 10.3. AstraZeneca PLC
  • 10.4. AptarGroup, Inc.
  • 10.5. MetP Pharma AG
  • 10.6. GlaxoSmithKline Inc.
  • 10.7. Hikma Pharmaceuticals PLC
  • 10.8. Currax Pharmaceuticals LLC.
  • 10.9. Tonix Medicines, Inc.
  • 10.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us